Cellectar Biosciences CLRB 深 沪
等待开盘 07-30 09:30:00 美东时间
4.71
-0.320
-6.36%
华盛通- 最 高5.11
- 今 开5.01
- 成交量 12.74万股
- 最 低 4.65
- 昨 收 5.03
- 总市值 2.17亿
- 52周最高 68.70
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 4.36
- 委 比 94.39%
- 总股本 4607.99万
- 历史最高 276000.00
- 量 比 0.71
- 振 幅 9.15%
- 历史最低 4.65
- 每 手 1
- 风险率 25.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CLEAR, an Official TSA PreCheck® Enrollment Provider, Expands Enrollment and Renewal Options by Opening a New Location at Aventura Mall in South Florida
CLEAR has launched a new TSA PreCheck enrollment location at Aventura Mall in Florida, offering consumers an additional convenient option to enroll or renew their Trusted Traveler program membership. This new location complements CLEAR's existing 62 airport-based enrollment points across the U.S. and reflects the company's ongoing expansion strategy. The new site is open Monday through Saturday from 11 a.m. to 7 p.m. ET and Sunday from noon to 7 ...
07-24 10:00
Cellectar Biosciences Has Been Granted European Patent Number EP3773544 Titled "PHOSPHOLIPID-FLAVAGLINE CONJUGATES AND METHODS OF USING THE SAME FOR TARGETED CANCER THERAPY".
https://data.epo.org/publication-server/publications/pdf?path=2025/30/DOC/EPNWB1/EP19784548NWB1/EP19784548NWB1.pdf
07-24 03:58
CLEAR to Provide Discounted TSA PreCheck® for Military Families
CLEAR is participating in TSA's initiative to offer discounted or free TSA PreCheck enrollment for military spouses and Gold Star families. Currently serving military spouses receive a $25 discount, while Gold Star families get free enrollment. CLEAR is also bringing mobile enrollment units to military installations to ease access. TSA PreCheck allows members to keep shoes, belts, and light jackets on during security checks and store laptops and ...
07-10 10:00
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
Cellectar Biosciences announced the closing of an underwritten public offering raising approximately $6.9 million. The offering included Class A and Class B Units, with proceeds to support general corporate purposes and initiate a Phase 1b study for CLR 125 in triple-negative breast cancer. The securities were registered with the SEC, and Ladenburg Thalmann acted as sole bookrunning manager.
07-02 20:15
CareCloud Joins Russell Microcap Index as Common Stock Price Rises 70% During Q2 2025
CareCloud,Inc., a leader in AI-driven healthcare technology solutions, has been added to the Russell Microcap® Index, effective June 30, 2025. This inclusion reflects growing recognition of the company's momentum in the healthcare technology sector. During Q2 2025, the company's stock price increased by approximately 70%, driven by key developments including the launch of its new AI Center of Excellence, resumption of acquisition activities, and ...
07-02 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neurogene (NASDAQ:NGNE) shares increased by 32.3% to $19.77 during Tue...
07-02 01:05
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
Cellectar Biosciences announced a $6 million underwritten public offering, offering Class A and B Units with warrants. Proceeds will fund general corporate purposes and a Phase 1b study of CLR 121125 for triple-negative breast cancer. The offering is expected to close on July 2, 2025, with Ladenburg Thalmann as the bookrunner. Additional details are available in the SEC filings.
07-01 13:25
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
Cellectar Biosciences and Nusano have signed a multi-year supply agreement for iodine-125 and actinium-225 to support Cellectar's radiotherapy programs, including a Phase 1b trial for triple-negative breast cancer. Nusano's Utah facility will produce these isotopes for commercial-stage therapeutics, ensuring a stable supply and advancing innovative treatments for cancer patients.
06-26 12:05
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
Cellectar Biosciences submitted a Phase 1b study protocol to the FDA for its Auger-emitting radiopharmaceutical CLR 125, targeting relapsed triple-negative breast cancer (TNBC). CLR 125 uses iodine-125 to directly target tumor nuclei and mitochondria, aiming to maximize efficacy while minimizing side effects. The study will evaluate three doses in 15 patients per arm, assessing safety, tolerability, and tumor uptake. TNBC, an aggressive breast ca...
06-24 12:30
